- Home
- USAU vs CTSO Comparison
USAU vs CTSO Comparison
Compare USAU & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USAU
- CTSO
- Stock Information
- Founded
- USAU N/A
- CTSO 1997
- Country
- USAU United States
- CTSO United States
- Employees
- USAU N/A
- CTSO N/A
- Industry
- USAU Precious Metals
- CTSO Medical/Dental Instruments
- Sector
- USAU Basic Materials
- CTSO Health Care
- Exchange
- USAU Nasdaq
- CTSO Nasdaq
- Market Cap
- USAU 68.1M
- CTSO 57.2M
- IPO Year
- USAU N/A
- CTSO N/A
- Fundamental
- Price
- USAU $7.07
- CTSO $0.90
- Analyst Decision
- USAU Strong Buy
- CTSO Strong Buy
- Analyst Count
- USAU 1
- CTSO 3
- Target Price
- USAU $11.00
- CTSO $4.67
- AVG Volume (30 Days)
- USAU 130.8K
- CTSO 155.7K
- Earning Date
- USAU 12-13-2024
- CTSO 11-07-2024
- Dividend Yield
- USAU N/A
- CTSO N/A
- EPS Growth
- USAU N/A
- CTSO N/A
- EPS
- USAU N/A
- CTSO N/A
- Revenue
- USAU N/A
- CTSO $37,739,531.00
- Revenue This Year
- USAU N/A
- CTSO $13.09
- Revenue Next Year
- USAU N/A
- CTSO $15.68
- P/E Ratio
- USAU N/A
- CTSO N/A
- Revenue Growth
- USAU N/A
- CTSO 1.80
- 52 Week Low
- USAU $3.20
- CTSO $0.70
- 52 Week High
- USAU $7.13
- CTSO $2.15
- Technical
- Relative Strength Index (RSI)
- USAU 67.37
- CTSO 42.35
- Support Level
- USAU $5.59
- CTSO $0.71
- Resistance Level
- USAU $6.50
- CTSO $0.99
- Average True Range (ATR)
- USAU 0.32
- CTSO 0.10
- MACD
- USAU 0.03
- CTSO 0.01
- Stochastic Oscillator
- USAU 96.33
- CTSO 51.39
About USAU U.S. Gold Corp.
U.S. Gold Corp is an exploration and development company that owns certain mining leases and other mineral rights comprising the CK Gold Project in Wyoming, the Keystone Project in Nevada, and the Challis Gold Project in Idaho.
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.